Venetoclax Basket Trial
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 30 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- Servier Pharmaceuticals LLC, Children's Cancer Research Fund, Gateway for Cancer Research, AbbVie, University of Colorado Cancer Center, Boston Children's Hospital
- Tags
- Hypomethylating Agents (HMA), Antimetabolites, BCL-2 Inhibitor, Chemotherapy, Steroid
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1610
- NCT Identifier
- NCT05292664
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.